Cardiff Oncology Inc (FRA:XE7C)
€ 2.975 -0.145 (-4.65%) Market Cap: 142.29 Mil Enterprise Value: 82.00 Mil PE Ratio: 0 PB Ratio: 2.53 GF Score: 50/100

Cardiff Oncology Inc at William Blair Biotech Focus Conference (Virtual) Transcript

Jul 15, 2021 / 04:00PM GMT
Release Date Price: €4.96 (-6.42%)
Andy Hsieh
William Blair & Company - Analyst

So this is our second day of the Biotech Focus Conference. So we are really privileged to have the CEO of Cardiff Oncology, Mark Erlander, to give us a little debrief about the progress that you've made. Obviously the KRAS space is really hot, and it seems like the activity of this compound has pan-cancer activity. So we're really excited to hear what you have to say. But before we do that, I have to disclose that for a full list of conflicts and disclosures, please go to our website, WilliamBlair.com, for a list of full disclosures.

Questions & Answers

Andy Hsieh
William Blair & Company - Analyst

So to start off, Mark, maybe it's been a great year for the Company. So maybe reflect on the past year and highlight some points for us, all the accomplishments, and what are you looking forward to in the next year, year and a half for the Company?

Mark Erlander
Cardiff Oncology, Inc. - CEO

Thank you. Thank you, Andy. And look, we are absolutely thrilled to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot